| Datopotamab Deruxtecan studied in …STUDIED_INderived48 of 48show fewer |
|---|
| → studied in | NCT06103864Phase 3 · recruiting A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215340Phase 3 · active not recruiting Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05061550Phase 2 · recruiting Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05489211Phase 2 · recruiting Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) · 48 trials list this drug (45 active) | — | — | Malignant Gastric Neoplasm,Malignant Biliary Tract Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357533Phase 3 · recruiting Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564844Phase 3 · active not recruiting A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644068Phase 1/Phase 2 · active not recruiting Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825753Phase 2 · not yet recruiting Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer · 48 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06244485Phase 1 · active not recruiting A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors · 48 trials list this drug (45 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07291037Phase 3 · recruiting Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07357597Phase 4 · recruiting An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. · 48 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03401385Phase 1 · active not recruiting First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460273Phase 1/Phase 2 · active not recruiting A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07205822Phase 3 · recruiting A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06130553Phase 1/Phase 2 · recruiting A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors · 48 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04656652Phase 3 · active not recruiting Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350097Phase 3 · recruiting Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533826Phase 2 · recruiting TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd · 48 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06822543Phase 2 · recruiting A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) · 48 trials list this drug (45 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05104866Phase 3 · active not recruiting A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07129993Phase 2/Phase 3 · recruiting Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma · 48 trials list this drug (45 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05417594Phase 1/Phase 2 · recruiting Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies · 48 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176261Phase 2 · recruiting DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,HER2-Negative Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742102Phase 1/Phase 2 · active not recruiting A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer · 48 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07738341Phase 1/Phase 2 · not yet recruiting GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04612751Phase 1 · active not recruiting Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07720284Phase 3 · recruiting An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC · 48 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06112379Phase 3 · active not recruiting A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07535437Phase 1/Phase 2 · recruiting A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098338Phase 2 · recruiting A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05555732Phase 3 · active not recruiting Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05629585Phase 3 · active not recruiting A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06954480Phase 2 · recruiting Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer · 48 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04526691Phase 1 · active not recruiting Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05374512Phase 3 · active not recruiting A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06417814Phase 3 · recruiting A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07582887recruiting Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01042379Phase 2 · recruiting I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer · 48 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05687266Phase 3 · active not recruiting Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069595Phase 2 · recruiting PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04484142Phase 2 · completed Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940325Phase 2 · active not recruiting Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer · 48 trials list this drug (45 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05117476Phase 1 · active not recruiting A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors · 48 trials list this drug (45 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05866432Phase 2 · recruiting Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06676917Phase 2 · withdrawn Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06279728approved for marketing Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients · 48 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03944772Phase 2 · active not recruiting Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) · 48 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06508216Phase 1/Phase 2 · recruiting A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer · 48 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |